SOX11 Antibody, HRP conjugated

1. Research findings demonstrate a critical role for SOX11 in normal kidney development, suggesting that variations in this gene may predispose individuals to CAKUT (Congenital Anomalies of the Kidney and Urinary Tract). PMID: 29459093
2. Studies have shown a negative correlation between miR-223 and the mRNA level of SOX11 in clinical samples. These findings indicate that miR-223 is repressed and correlated with high-risk clinical features in MCL (Mantle Cell Lymphoma), suggesting its potential as a target for optimizing MCL management. PMID: 29158064
3. SOX11 hypermethylation has been linked to adverse clinicopathological characteristics of prostate cancer. PMID: 29315911
4. Research confirms the high specificity of SOX11 expression as a molecular marker for minimal residual disease in mantle cell lymphoma. PMID: 29520657
5. Both SOX11 and TFE3 have been found to be overexpressed in solid-pseudopapillary neoplasms (SPNs) and may play a role in their pathogenesis. PMID: 29272888
6. Studies investigated the association between miR-211-5p and SOX11 in relation to proliferation, viability, and invasion of human thyroid cancer (TC) cells. The findings revealed that miR-211-5p was upregulated and SOX11 was downregulated in TC tissues and cell lines. Inhibiting SOX11 suppressed the proliferation and invasion of TC cells, indicating that miR-211-5p plays a role in regulating these processes through targeting SOX11 expression. PMID: 28703321
7. REVIEW: This review delves into the implications of SOX11 overexpression and frequent genetic lesions, particularly in cooperation with cyclin D1, in the pathogenesis of mantle cell lymphoma. PMID: 28466437
8. Research sheds new light on the biology of mantle cell lymphoma (MCL), highlighting the role of SOX11 in exerting a functional effect through the repression of BCL6 transcription in MCL cells. PMID: 26710884
9. Studies revealed, for the first time, that HIG-2 and SOX11 mutually co-regulate each other, and that knocking down either gene promotes increased proliferation in a non-synergistic manner in primary mantle cell lymphoma cells. PMID: 26757780
10. Solid pseudopapillary neoplasms (SPNs) showed positive staining for SRY-related high-mobility group box 11 (SOX-11), transcription factor E3 (TFE3), and beta-catenin on cell blocks. PMID: 29045075
11. SOX11 (sex determining region Y-box 11) was inversely expressed with miR-223-3p in ovarian cancer (OC) cell lines and tissue specimens. miR-223-3p mimic decreased SOX11 expression. Overexpressing SOX11 inhibited ovarian cancer cell proliferation and invasion, suggesting that miR-223-3p regulates OC cell proliferation and invasion by targeting SOX11 expression. PMID: 28587313
12. Research demonstrates that SOX11 is a crucial regulator of multiple basal-like breast cancer phenotypes, including growth, migration, invasion, and expression of signature basal-like breast cancer genes. PMID: 26894864
13. Findings suggest that SOX11 is a potential biomarker for ductal carcinoma in situ lesions containing cells with distinct biological features that are likely to progress to invasive breast cancer. PMID: 28707729
14. SOX11 antigen can be reliably detected in decalcified tissue bone marrow tissue from mantle cell lymphoma patients. PMID: 27720733
15. Results suggest that SOX11 promotes MCL homing and invasion, and increases CAM-DR (Chemoresistance) through the direct regulation of CXCR4 and FAK expression, as well as FAK/PI3K/AKT pathway activation, contributing to a more aggressive phenotype. PMID: 28533307
16. Analysis of 28 other patients with CHARGE syndrome showed no SOX11 copy number changes or pathogenic sequence variants. This child's chromosomal abnormality is unique and represents the first co-occurrence of duplication 2p25 and clinical features of CHARGE syndrome. PMID: 26850571
17. SOX11 immunohistochemistry could be a useful adjunct in distinguishing secondary cutaneous mantle cell lymphoma from primary cutaneous B-cell lymphomas. PMID: 26762898
18. BLIMP1 and XBP1 expression was significantly more frequent in SOX11-negative cases than in SOX11-positive cases. PMID: 26360498
19. SOX11 is a useful marker in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. PMID: 22642745
20. Deletion or mutation of SOX11 can result in a Coffin-Siris phenotype. PMID: 26543203
21. SOX11's ability to reduce effector caspase activity is reflected in its capacity to reduce cell death following toxic insult. Notably, other SOX proteins also demonstrate the ability to reduce caspase-6 activity, but to a lesser extent than SOX11. PMID: 26505998
22. Results show that in non-malignant cells, SOX11 is strongly marked by enrichment of H3K27me3, while tumors in general show promoter DNA methylation. PMID: 25880212
23. This research explores the utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes. PMID: 25887497
24. Implementing the detection of SOX11 in diagnostic flow cytometry would be beneficial for accurate and reliable diagnosis of MCL, especially for distinguishing cases of MCL and B-CLL/SLL with aberrant immune phenotypes. PMID: 25120048
25. Research indicates that aberrant SOX11 gene promoter methylation may underlie its down-regulation in Gastric cancer. PMID: 25801783
26. These findings suggest that differential miRNA expression in neurons could contribute to an altered function of the transcription factor SOX11 and other genes in the context of epilepsy. PMID: 25766675
27. SOX11 overexpression suppresses PCa (Prostate Cancer) cell migration and invasion. These findings demonstrate that SOX11 could suppress cell proliferation, migration, and invasion of PCa in vitro. PMID: 25773392
28. These results point to SOX11 as a possible biomarker that provides new biological insights, contributing to a better understanding of this pathology. PMID: 25608839
29. De novo SOX11 mutations cause Coffin-Siris syndrome. Sox11 is expressed in fetal brain and adult brain and heart tissue. PMID: 24886874
30. Currently, there are conflicting perspectives on the association of SOX11 gene expression and outcome in MCL, with some studies linking the lack of SOX11 expression to a good prognosis, while others find it associated with an adverse clinical course. PMID: 24736261
31. SOX11 directly binds to genes in critical intracellular pathways controlling cell cycle and proliferation in MCL. PMID: 24681958
32. High nuclear SOX11 expression has been associated with more prolonged overall survival. PMID: 25041022
33. High SOX11 expression is associated with mantle cell lymphoma. PMID: 25056830
34. PDGFA is a direct target gene of SOX11, upregulated in MCL cells, and its inhibition has been shown to impair SOX11-enhanced in vitro angiogenic effects on endothelial cells. PMID: 25092176
35. Immunohistochemical (IHC) analysis revealed protein expression of all four genes. IHC staining for ADAM12, FAP, and WISP1 correlated with CDR (Complete Disease Response) and was higher, whereas SOX11 staining was lower in tumors with earlier recurrence following excision. PMID: 24402778
36. Results indicate that SOX11 is a potential tumor suppressor and an independent positive prognostic factor in gastric cancer patients with less advanced clinicopathological features. PMID: 24604109
37. This is the first report demonstrating that quantification of SOX11 can be used as a minimal residual disease marker, comparable to the key translocation t(11;14), in Mantle cell lymphoma. PMID: 24878000
38. Patients with SOX11 expression showed a shorter TTT (Time to Treatment), and SOX11-expressing MCL patients exhibited a potentially more indolent course. However, further analyses within a larger cohort are warranted to confirm the independent diagnostic role of SOX11 expression. PMID: 23648671
39. SOX11 is overexpressed in cutaneous malignant melanoma patients. PMID: 23867449
40. This research characterizes new monoclonal anti-SOX11 antibodies, suitable for Western blot assay and immunohistochemistry. PMID: 24145648
41. SOX11 is unable to differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas. PMID: 24225745
42. Statistically significant differences in SOX11 mRNA expression were observed between mantle cell lymphoma and other B-cell non-Hodgkin lymphomas. PMID: 22967417
43. This study highlights the importance of Sox11 expression as a favorable prognosticator in glioblastomas. PMID: 23619925
44. These findings confirm the significance of SOX11 as a diagnostic antigen in MCL, as 100% of tissue microarray (TMA) cases exhibit bright nuclear staining using the SOX11-C1 antibody in IHC-P (Immunohistochemistry). PMID: 22738398
45. SOX11 contributes to tumor development by altering the terminal B-cell differentiation program of mantle cell lymphoma. PMID: 23321250
46. Downregulation of SOX11 is associated with neurodevelopmental defects in trisomies 21. PMID: 22752091
47. Significant differences were observed between the expression levels of SOX11 in patients with mantle cell lymphoma at diagnosis (n = 21) and in healthy donors (n = 18) (blood: P < 0.0001; marrow: P = 0.0001). PMID: 22827557
48. Observations suggest that MCL with mutated IGHV, SOX11-negativity, and non-nodal presentation correspond to a subtype of the disease with more indolent behavior. PMID: 22915760
49. High expression of SOX11 is associated with mantle cell lymphoma. PMID: 21479697
50. In vitro studies demonstrated a SOX11-dependent regulation of mantle cell lymphoma-specific gene expression. PMID: 21880559

Show More

Hide All

HGNC: 11191

OMIM: 600898

KEGG: hsa:6664

STRING: 9606.ENSP00000322568

UniGene: Hs.432638